Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study.

androgen receptor multi-institutional study prognosis triple-negative breast cancer

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
17 Jul 2019
Historique:
received: 13 06 2019
revised: 05 07 2019
accepted: 11 07 2019
entrez: 20 7 2019
pubmed: 20 7 2019
medline: 20 7 2019
Statut: epublish

Résumé

The androgen receptor (AR) has emerged as a potential therapeutic target for AR-positive triple-negative breast cancer (TNBC). However, conflicting reports regarding AR's prognostic role in TNBC are putting its usefulness in question. Some studies conclude that AR positivity indicates a good prognosis in TNBC, whereas others suggest the opposite, and some show that AR status has no significant bearing on the patients' prognosis. We evaluated the prognostic value of AR in resected primary tumors from TNBC patients from six international cohorts {US ( AR status shows population-specific patterns of association with patients' overall survival after controlling for age, grade, population, and chemotherapy. We found AR-positive status to be a marker of good prognosis in US and Nigerian cohorts, a marker of poor prognosis in Norway, Ireland and Indian cohorts, and neutral in UK cohort. AR status, on its own, is not a reliable prognostic marker. More research to investigate molecular subtype composition among the different cohorts is warranted.

Sections du résumé

BACKGROUND BACKGROUND
The androgen receptor (AR) has emerged as a potential therapeutic target for AR-positive triple-negative breast cancer (TNBC). However, conflicting reports regarding AR's prognostic role in TNBC are putting its usefulness in question. Some studies conclude that AR positivity indicates a good prognosis in TNBC, whereas others suggest the opposite, and some show that AR status has no significant bearing on the patients' prognosis.
METHODS METHODS
We evaluated the prognostic value of AR in resected primary tumors from TNBC patients from six international cohorts {US (
RESULTS RESULTS
AR status shows population-specific patterns of association with patients' overall survival after controlling for age, grade, population, and chemotherapy. We found AR-positive status to be a marker of good prognosis in US and Nigerian cohorts, a marker of poor prognosis in Norway, Ireland and Indian cohorts, and neutral in UK cohort.
CONCLUSION CONCLUSIONS
AR status, on its own, is not a reliable prognostic marker. More research to investigate molecular subtype composition among the different cohorts is warranted.

Identifiants

DOI: 10.3390/cancers11070995 PMID: 31319547 PMC: PMC6678933
pubmed: 31319547
pii: cancers11070995
doi: 10.3390/cancers11070995
pmc: PMC6678933
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : National Cancer Institute at the National Institute of Health
ID : U01 CA179671 and R01 CA169127

Références

Med Oncol. 2012 Jun;29(2):406-10
pubmed: 21264529
Med Oncol. 2012 Jun;29(2):526-33
pubmed: 21519872
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
EMBO J. 2011 Jun 24;30(15):3019-27
pubmed: 21701558
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Am J Clin Pathol. 2012 Oct;138(4):511-6
pubmed: 23010705
Acta Histochem. 2013 May;115(4):344-8
pubmed: 23031358
Breast Cancer Res. 2013 May 11;15(3):R37
pubmed: 23663520
Clin Cancer Res. 2013 Oct 1;19(19):5533-40
pubmed: 23948975
Ann Surg Oncol. 2014 Feb;21(2):361-7
pubmed: 24046116
Breast Cancer Res. 2014 Jan 22;16(1):R7
pubmed: 24451109
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Cancers (Basel). 2017 Jan 06;9(1):null
pubmed: 28067809
Cancer Res. 2017 Jul 1;77(13):3455-3466
pubmed: 28512248
Cell Physiol Biochem. 2017;43(5):2047-2061
pubmed: 29059676
Zhonghua Yi Xue Za Zhi. 2018 Feb 27;98(8):601-605
pubmed: 29534389
Oncotarget. 2018 May 29;9(41):26406-26416
pubmed: 29899867
PLoS One. 2018 Jun 18;13(6):e0196909
pubmed: 29912871
Cancer Treat Rev. 2018 Jul;68:102-110
pubmed: 29940524
Curr Oncol Rep. 2018 Aug 20;20(10):76
pubmed: 30128845

Auteurs

Shristi Bhattarai (S)

Department of Biology, Georgia State University, Atlanta, GA 30303, USA.

Sergey Klimov (S)

Department of Biology, Georgia State University, Atlanta, GA 30303, USA.

Karuna Mittal (K)

Department of Biology, Georgia State University, Atlanta, GA 30303, USA.

Uma Krishnamurti (U)

Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA.
International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA.

Xiaoxian Bill Li (XB)

Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA.
International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA.

Gabriela Oprea-Ilies (G)

Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322, USA.

Ceyda Sonmez Wetherilt (CS)

Department of Biology, Georgia State University, Atlanta, GA 30303, USA.

Ansa Riaz (A)

Department of Biology, Georgia State University, Atlanta, GA 30303, USA.

Mohammed A Aleskandarany (MA)

Nottingham Breast Cancer Research Center, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham NG5 1PB, UK.
ORCID: 0000-0001-5538-5946

Andrew R Green (AR)

Nottingham Breast Cancer Research Center, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham NG5 1PB, UK.
ORCID: 0000-0002-0488-5913

Ian O Ellis (IO)

International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA.
Nottingham Breast Cancer Research Center, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham NG5 1PB, UK.

Guilherme Cantuaria (G)

Department of Gynecologic Oncology, Northside Hospital Cancer Institute, Atlanta, GA 30342, USA.

Meenakshi Gupta (M)

Department of Pathology, Piedmont Newnan Hospital, Newnan, GA 30265, USA.

Upender Manne (U)

Department of Translational Anatomic Physiology, University of Alabama at Birmingham, Birmingham, AL 3300, USA.

Johnson Agboola (J)

International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA.
Morbid Anatomy and Histopathology Department, Olabisi Onabanjo University, Ogun 112106, Nigeria.

Brett Baskovich (B)

Department of Pathology, University of South Alabama College of Medicine, AL 36688, USA.

Emiel A M Janssen (EAM)

International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA.
Department of Pathology, Stavanger University Hospital, 4002 Stavanger, Norway.

Grace Callagy (G)

International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA.
Discipline of Pathology, NUI Galway, Lambe Institute for Translational Research, Costello Road, H91 TK33 Galway, Ireland.

Elaine M Walsh (EM)

Discipline of Pathology, NUI Galway, Lambe Institute for Translational Research, Costello Road, H91 TK33 Galway, Ireland.
ORCID: 0000-0002-9950-5978

Anurag Mehta (A)

International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA.
Research Department, Rajiv Gandhi Cancer Institute and Research Centre, Delhi 110-085, India.

Atika Dogra (A)

Research Department, Rajiv Gandhi Cancer Institute and Research Centre, Delhi 110-085, India.

Tanuja Shet (T)

International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA.
Department of Pathology, Tata Memorial Hospital, Mumbai 400 012, India.

Pooja Gajaria (P)

Department of Pathology, Tata Memorial Hospital, Mumbai 400 012, India.
ORCID: 0000-0001-8412-3996

Tiffany Traina (T)

Department of Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 90710, USA.
ORCID: 0000-0003-3597-0050

Haruna A Nggada (HA)

International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA.
Department of Human Pathology, Faculty of Basic Clinical Sciences, College of Medical Sciences, University of Maiduguri, Maiduguri, Borno state 1069, Nigeria.

Abidemi Omonisi (A)

International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA.
Department of Anatomic Pathology, Ekiti State University, Ado-Ekiti PMB 5363, Nigeria.

Saad A Ahmed (SA)

International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA.
Department of Pathology, Ahmadu Bello University, Zaria, Kaduna State 810241, Nigeria.
ORCID: 0000-0001-8194-5943

Emad A Rakha (EA)

International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA.
Nottingham Breast Cancer Research Center, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham NG5 1PB, UK.

Padmashree Rida (P)

Department of Biology, Georgia State University, Atlanta, GA 30303, USA. prida@gsu.edu.
International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA. prida@gsu.edu.

Ritu Aneja (R)

Department of Biology, Georgia State University, Atlanta, GA 30303, USA. raneja@gsu.edu.
International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State University, Atlanta, GA 30303, USA. raneja@gsu.edu.

Classifications MeSH